Pfizer Inc.
NYSE:PFEDrug Manufacturers - General
-$0.71 today
- Market cap
- $159.94B
- Beta
- 0.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.32
- Dividend yield
- 6.82%
Volume 37.37M
Average 36.66M
PFE Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Pfizer Inc.NYSE: PFE
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables falls 22.4% from a year ago
Net receivables stood at $12.49B at the end of Q2 FY2026, down 22.4% from a year earlier and down 0.8% from the prior quarter. Over 3 fiscal years it compounded at +2.9% a year.
Context
- Net receivables amounted to 6.2% of total assets at the end of Q2 FY2026, down 1.6 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -22.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 15.84B USD
- Year-over-year change
- +7.2%
- 4-year CAGR
- +0.2%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.84B | +7.2% |
| FY2024 | 2024-12-31 | 14.78B | -4.9% |
| FY2023 | 2023-12-31 | 15.54B | +7.0% |
| FY2022 | 2022-12-31 | 14.53B | -7.7% |
| FY2021 | 2021-12-31 | 15.75B | — |
Net Receivables vs competitors
How PFE compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -22.4% is the 9th highest of 11, against a peer median of +7.6%.
- Net receivables amounts to 6.2% of total assets for PFE, versus a peer median of 10.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $23.48B USD | +36.4% | +33.0% | 16.5% | |
| Sep 2026 | $18.99B USD | +7.8% | +0.5% | 9.6% | |
| Sep 2026 | $16.35B USD | +14.0% | +18.2% | 13.7% | |
| Jun 2026 | $13.82B USD | +9.4% | +3.8% | 10.2% | |
| Jun 2026 | $12.56B USD | +6.1% | +10.3% | 9.7% | |
| Jun 2026 | $12.49B USD | -22.4% | +2.9% | 6.2% | |
| Jun 2026 | $10.55B USD | -30.1% | +1.4% | 12.0% | |
| Jun 2026 | $9.85B USD | +7.4% | +3.4% | 8.1% | |
| Jun 2026 | €9.21B EUR | +12.2% | +0.9% | 7.1% | |
| Jun 2026 | £8.03B GBP | -23.9% | +7.6% | 13.1% | |
| Jun 2026 | $5.06B USD | +5.7% | +0.9% | 10.2% | |
| Peer median (excluding PFE) | — | +7.6% | +3.6% | 10.2% | |
Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.94B | 416M | 2.85B | 1.04B | 1.14B |
| Short-term Investments | 29.13B | 22.32B | 9.84B | 19.43B | 12.45B |
| Net Receivables | 15.75B | 14.53B | 15.54B | 14.78B | 15.84B |
| Inventory | 9.06B | 8.98B | 10.19B | 10.85B | 10.65B |
| Other Current Assets | 3.82B | 5.02B | 4.91B | 4.25B | 2.81B |
| Total Current Assets | 59.69B | 51.26B | 43.33B | 50.36B | 42.9B |
| Property, Plant & Equipment (Net) | 14.88B | 16.27B | 18.94B | 18.39B | 21.53B |
| Goodwill | 49.21B | 51.38B | 67.78B | 68.53B | 71.26B |
| Intangible Assets | 25.15B | 43.37B | 64.9B | 55.41B | 53.73B |
| Long-term Investments | 21.53B | 15.07B | 15.37B | 2.23B | 1.74B |
| Tax Assets | 3.34B | 6.69B | 3.71B | 8.66B | 9.7B |
| Other Non-current Assets | 7.68B | 13.16B | 12.47B | 9.82B | 7.3B |
| Total Non-current Assets | 121.78B | 145.94B | 183.17B | 163.04B | 165.26B |
| Total Assets | 181.48B | 197.21B | 226.5B | 213.4B | 208.16B |
| Account Payables | 5.58B | 6.81B | 6.71B | 5.63B | 5.24B |
| Short-term Debt | 2.24B | 2.93B | 10.35B | 6.95B | 3.48B |
| Tax Payables | 1.27B | 1.59B | 2.35B | 0 | 0 |
| Deferred Revenue | 3.07B | 2.52B | 2.7B | 1.51B | 784M |
| Other Current Liabilities | 28.27B | 25.99B | 23.32B | 23.2B | 18.32B |
| Total Current Liabilities | 42.67B | 42.14B | 47.79B | 43B | 36.98B |
| Long-term Debt | 34.76B | 31.93B | 60.5B | 57.41B | 61.64B |
| Deferred Tax Liabilities | 349M | 1.02B | 640M | 2.12B | 2.4B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 26.24B | 26.2B | 28.28B | 20.09B | 18.07B |
| Total Non-current Liabilities | 61.34B | 59.15B | 89.42B | 81.9B | 84.4B |
| Total Liabilities | 104.01B | 101.29B | 137.21B | 124.9B | 121.39B |
| Common Stock | 473M | 476M | 478M | 480M | 481M |
| Retained Earnings | 103.39B | 125.66B | 118.35B | 116.73B | 114.61B |
| Accumulated OCI | (5.9B) | (8.3B) | (7.96B) | (7.84B) | (8.07B) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 262M | 256M | 274M | 294M | 299M |
| Total Equity | 77.46B | 95.92B | 89.29B | 88.5B | 86.78B |
| Total Debt | 37B | 34.86B | 70.85B | 66.99B | 67.42B |
| Net Debt | 35.05B | 34.44B | 67.99B | 65.95B | 66.27B |
Pfizer Inc.
NYSE:PFE
Intrinsic Alpha fair value
Locked
Current Price
$28.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.